baber/WOPTO huggingface dataset:
Patent EA-001905-B1 (EA)
Title: Gelatine encapsulated solution dosage forms of sertraline
Inventor: CURATOLO WILLIAM JOHN
IPC: A61P25/24
Filed: 1998-06-16
Abstract: 1. A dosage form comprising a gelatin-encapsulated composition comprising sertraline, or a pharmaceutically acceptable salt thereof, and a water immiscible vehicle. 2. A dosage form as defined in Claim 1, which decreases Tmax time, by which the maximum concentration of sertraline in blood plasma is reached , at least 0.5 hr in comparison with oral forms with direct deliverance. 3. A dosage form as defined in Claim 1, which decreases Tmax time, by which the maximum concentration of sertraline in blood plasma is reached , at least one hour in comparison with oral forms with direct deliverance. 4. A dosage form as defined in Claim 1, containing 10 mgA to 300 mgA of sertraline. 5. A dosage form as defined in Claim 4, containing 10 mgA to 250 mgA of sertraline. 6. A dosage form as defined in Claim 5, containing 10 mgA to 100 mgA of sertraline. 7. A dosage form as defined in Claim 1, wherein said vehicle comprises a mono-, di-, or triglyceride, or a mixture thereof. 8. A dosage form as defined in Claim 7, wherein the acyl chain(s) of said mono-, di-, or triglyceride average 4-18 carbons in length. 9. A dosage form as defined in Claim 8, wherein the acyl chain(s) of said mono-, di-, or triglyceride average 6-14 carbons in length. 10. A dosage form as defined in Claim 1, wherein said vehicle is liquid at 37 degree C. 11. A dosage form as defined in Claim 1, wherein said vehicle comprises a vegetable oil. 12. A dosage form as defined in Claim 11, wherein said vegetable oil is selected from corn oil, peanut oil, sesame oil, olive oil, castor oil, coconut oil, cottonseed oil, soybean oil, or safflower oil. 13. A dosage form as defined in Claim 1, wherein said vehicle comprises a surfactant or emulsifier. 14. A dosage form as defined in Claim 13, wherein said surfactant or emulsifier is selected from polysorbate-80, nonylphenoxypolyoxyethylene, dioctyl sodium sulfosuccinate, PEG-6-glycerylmonooleate, or PEG-6-glyceryllinoleate. 15. A dosage form as defined in Claim 1, wherein said vehicle comprises a fatty acid. 16. A dosage form as defined in Claim 15, wherein said fatty acid is selected from caprylic acid, capric acid, lauric acid, oleic acid, or linoleic acid. 17. A dosage form as in Claim 1, wherein said dosage form comprises a liquid ester of a short chain alcohol and acid. 18. A dosage form as in Claim 17, wherein said ester is selected from the propylene glycol esters of caprylic and/or capric acids. 19. A dosage form as in Claim 1, wherein said vehicle additionally comprises an alcohol. 20. A dosage form as in Claim 19, wherein said alcohol is polyethyleneglycol, glycerin, ethanol, or propyleneglycol. 21. A dosage form as defined in Claim 1, which decreases precipitation of sertraline in a chloride ion containing use environment relative to a comparison dosage form made with a water-miscible vehicle. 22. A method of treating an illness amenable to treatment with sertraline, comprising administering to a person in need of such treatment a dosage form as defined in Claim 1.
Patent EA-007413-B1 (EA)
Title: Polypeptide for resuscitating dormant, moribund or latent bacterial cells, nucleic acid encoding thereof and methods of using polypeptide and nucleic acid
Inventor: MUKAMOLOVA GALINA V
IPC: C12N15/11
Filed: 1998-06-03
Abstract: The present invention relates to an isolated polypeptide stimulating resuscitating dormant, moribund or latent bacterial cells, to nucleic acid encoding thereof, to a vector comprising said nucleic acid, to an antibody or a derivative thereof specific to the isolated polypeptide, to a pharmaceutical composition comprising said polypeptide, the nucleic acid and the vector and to use thereof in therapy, e.g. immunotherapy, diagnosis or prophylaxis of infections, and also to a receptor of the isolated polypeptide. The present invention further comprises a diagnostic kit capable of resuscitating dormant, moribund or latent bacterial cells, a culture or transport medium for bacterial cells, comprising the polypeptide.
Patent EA-005892-B1 (EA)
Title: Method for preparing anticancer compounds
Inventor: LEHNER RICHARD SHELTON
IPC: A61K31/505
Filed: 2000-03-30
Abstract: The present invention relates to a method for preparing compounds of the formula 9: wherein R<6>, R<7>, R<8>, R<9>, R<10> and R<15> are as defined herein. The foregoing compounds are useful in the treatment of hyperproliferative disorders, such as cancers, in mammals.
Patent EA-014824-B1 (EA)
Title: Molecularly imprinted polymer selective to nitrosamines, method for manufacturing thereof (variants), kit, smoking article and a filter comprising polymer and methods of using polymer
Inventor: BHATTACHARYYA SUMITA
IPC: A24B15/24
Filed: 2005-05-24
Abstract: Molecularly imprinted polymer derived from at least one functional polymer comprising an acid functional group, selective to at least one specific to tobacco nitrosamine, wherein he polymer has molecularly imprinted matrix specific to tobacco nitrosamine or a functional or structural analogue thereof. There also described variants of a method for manufacturing such polymer, and a kit, a smoking article and a smoke filter, comprising polymer, and methods for using polymer.
Patent EA-010745-B1 (EA)
Title: Method for the production of propylene from propane
Inventor: CRONE SVEN
IPC: C07C11/06
Filed: 2005-12-20
Abstract: The invention relates to a method for the production of propene from propane comprising the steps:A) a feed gas stream containing propane is prepared,B) the feed gas stream containing propane a and an oxygen-containing gas stream are supplied to a dehydrogenation zone and propane is subjected to a non-oxidative catalytic autothermal dehydrogenation to give propene, whereby a product gas stream b containing propane, propene, methane, ethane, ethene, nitrogen, carbon monoxide, carbon dioxide, water vapour and hydrogen is obtained,C) the product gas stream b is cooled and water vapour separated off by condensation to give a product as stream c stripped of water vapour,D); non-condensable or low-boiling gas components are separated off by bringing the product gas stream c into contact with an inert absorption agent with subsequent desorption of the gases dissolved in the inert absorption agent, whereby a Chydrocarbon stream d1 and a waste-gas stream d2, containing methane, ethane, ethene, nitrogen, carbon monoxide, carbon dioxide and hydrogen are generated,E) the Chydrocarbon stream d1 is cooled and compressed, to give a liquid Chydrocarbon stream e1,F) the liquid Chydrocarbon stream e1 is fed to a first distillation zone and separated by distillation into a stream f1 containing propane and propene and a stream f2 containing ethane and ethene andG) the stream f1 is fed to a second distillation zone and separated by distillation into a product gas stream g1 of propene and a stream g2 of propane,; whereby the stream g2 is at least partly recycled into the dehydrogenation zone.
Patent EA-014919-B1 (EA)
Title: Pyridine[3,4-b]pyrazinones
Inventor: HUGHES ROBERT O
IPC: A61K31/4985
Filed: 2007-04-10
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I:wherein R, R, Rand Rare as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediates are also disclosed.
Patent EA-016715-B1 (EA)
Title: Method for removal of materials from a liquid stream
Inventor: LARSEN CHRISTIAN KLEIN
IPC: C02F1/56
Filed: 2007-03-30
Abstract: A method for removal of dissolved materials and/or particles from a liquid stream comprising flocculation by vigorously mixing polysaccharides or hydrocolloids into the liquid stream and subsequent gelation of the polysaccharides or hydrocolloids with cations capable of gelling same. Large, strong gelled agglomerates of pollutant and polysaccharide or hydrocolloid are formed with the help of suitable cations. The gelled agglomerates are well suited to separation from a liquid stream by flotation, in a sieve, in a centrifuge, in a cyclone or via other conventional separation processes. Also described is a method for mixing of un-dissolved polysaccharide or hydrocolloid with a polluted aqueous stream by shearing the polysaccharide or hydrocolloid into the aqueous stream to improve logistics and provide economic savings in treatment of large volumes of water. Also described is the use of dilute solutions of polysaccharides for treatment of a variety of effluent streams. An application of the invention is provided for removal of hydrocarbons within the oil industry, but also for other kinds of oil-containing water and also water with organic or particulate pollution.
Patent EA-019971-B1 (EA)
Title: Aldolases, nucleic acids encoding them and methods for making and using them
Inventor: BURKE ELLEN
IPC: A23L27/30
Filed: 2007-03-07
Abstract: This invention relates to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In some embodiments, the invention is directed to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides in accordance with the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts.; In some embodiments, the invention provides polypeptides and biosynthetic pathways that are useful in the production of R-2-hydroxy 2-(indol-3-ylmethyl)-4-keto glutaric acid (R-MP) and certain stereoisomers of monatin, such as R,R- and S,R-monatin, and salts thereof, as well as certain stereoisomers of monatin derivatives, such as the R,R- and S,R-configurations, and salts thereof.
Patent EA-018500-B1 (EA)
Title: Screed strip
Inventor: CHATOVICH EVGENIJ STANISLAVOVICH
IPC: E04F21/00
Filed: 2010-08-25
Abstract: The invention relates to devices for construction plastering and can be used in plastering internal and external surfaces in industrial buildings and living spaces. A screed strip consists of a leveling element 1 embodied as a string of an indefinite length, a mark 2 embodied as an eccentric hole in a bolt head in which the string is arranged, a tightening mechanism comprising channel bars 4 with holes 5 and 6 accordingly for fixing the screed strip to the working surface and for tightening bolts 7 with nuts 8.
Patent EA-026111-B1 (EA)
Title: Pesticidal proteins and methods for their use
Inventor: SAMPSON KIMBERLY S
IPC: A01N63/50
Filed: 2010-02-26
Abstract: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated toxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO: 50-96, or the nucleotide sequence set forth in SEQ ID NO: 1-20, as well as variants and fragments thereof.
Patent EA-021383-B1 (EA)
Title: Herbicide composition
Inventor: YAMAJI YOSHIHIRO
IPC: A01P13/02
Filed: 2007-12-20
Abstract: The invention relates to a herbicidal composition, which is highly safe to useful crops and can exert a controlling effect on various weeds causing troubles for instance in paddy fields, upland fields or non-crop land over a wide range from pre-budding stage to the growing stage. The herbicidal composition, comprising the following component A, which represents at least one compound selected from the group consisting of isoxazoline derivatives represented by the formula [I] and salts thereof and the following component B as active ingredients. Component A:wherein each of Rand Rwhich are independent of each other, is a hydrogen atom, a C-Calkyl group, a C-Ccycloalkyl group or a C-Ccycloalkyl-C-Calkyl group, each of Rand Rwhich are independent of each other, is a hydrogen atom, a C-Calkyl group, a C-Ccycloalkyl group, or R, R, Rand Rmay form a 5- to 8-membered ring together with the carbon atoms to which they are bonded, each of Rand Rwhich are independent of each other, is a hydrogen atom or a C-Calkyl group, Y is a 5- or 6-membered aromatic heterocyclic or aromatic condensed heterocyclic group having an optional heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom. Component B-14: auxin synthesis inhibitors selected from: (a) phenoxycarboxylic acid derivatives: clomeprop, 2,4-D, 2,4-DB, dichlorprop, dichlorprop-P, MCPA, MCPB, mecoprop, mecoprop-P, MCPA-thioethyl; (b) benzoic acid derivatives: 2,3,6-TBA, chloramben; (c) pyridine carboxylic acid derivatives: fluoroxypyr, picloram, triclopyr; (d) quinoline carboxylic acid derivative: quinclorac; (e) benzothiazole derivative: benazolin.
Patent EA-021169-B1 (EA)
Title: Water-conducting household appliance comprising a dosing device and an input device
Inventor: GREGER THORALF
IPC: D06F39/02
Filed: 2010-09-02
Abstract: A water-conducting household appliance 1, such as a laundry treatment appliance for washing laundry, comprising a dosing device 11, at least one receptacle 6 that is used for storing at least one treatment substance, a treatment zone 16, a controller 14, an indicator 25 and an input device 26. The input device 26 allows a basic dosed amount of the treatment substance that is stored in the receptacle 6 to be adjusted. Furthermore, the controller 14 controls the dosing device 11 during the program cycle in order to dose the treatment substance for the treatment zone 16 on the basis of at least the basic dosed amount of treatment substance. The input device 26 allows the receptacle 6 in which the treatment substance is stored to be directly selected in order to adjust the basic dosed amount of treatment substance, and comprises at least one knob 32, 33 for direct adjustment for a user of a basic dosed amount of the treatment substance by pressing said knob during the predetermined minimum time period.
Patent EA-020488-B1 (EA)
Title: Derivatives of purine or deazapurine useful for the treatment of viral infections and other diseases
Inventor: HALCOMB RANDALL L
IPC: C07D473/34
Filed: 2010-10-15
Abstract: The present application includes novel modulators of TLRs, compositions containing such compounds, therapeutic methods that include the administration of such compounds.
Patent EA-025508-B1 (EA)
Title: Method and device for the treatment of skin lesions
Inventor: LIND ZECHARIA
IPC: A61B17/50
Filed: 2011-02-03
Abstract: A tweezers device for the application of cryogenic matter directly on a skin lesion while protecting the collateral skin tissue from being damaged by the cryogenic matter; the device comprises an applicator body configured with opposing tweezer arms; each tweezer arm includes a cryogenic matter application element such that when the opposing tweezer arms are closed about the skin lesion, the skin lesion is substantially encased by the cryogenic matter application elements.
Patent EA-033369-B1 (EA)
Title: Mutant interleukin-2 polypeptides with reduced affinity to the high-affinity il-2 receptor and preserved affinity to the intermediate-affinity il-2 receptor, and use thereof
Inventor: AST OLIVER
IPC: C12N15/26
Filed: 2012-02-07
Abstract: Described herein are a mutant interleukin-2 (IL-2) polypeptide comprising three amino acid mutations corresponding to amino acid substitutions F42A, Y45A and L72G in the sequence of human IL-2 (SEQ ID NO: 1), wherein said mutations abolish or reduce affinity of the mutant IL-2 polypeptide to the high-affinity IL-2 receptor and preserve affinity of the mutant IL-2 polypeptide to the intermediate-affinity IL-2 receptor compared to a wild-type IL-2 polypeptide, or a mutant interleukin-2 (IL-2) polypeptide comprising the amino acid sequence SEQ ID NO: 15 or SEQ ID NO: 19, which exhibits reduced or abolished affinity to the high-affinity IL-2 receptor and preserved affinity to the intermediate-affinity receptor compared to a wild-type IL-2 polypeptide. In addition, described are an isolated polynucleotide encoding said polypeptide, an expression vector and host cells comprising said isolated polynucleotide. Further described are a method for producing said mutant polypeptides, pharmaceutical compositions comprising said polypeptides, methods of treating cancer and stimulating the immune system where said compositions are used.
Patent EA-034500-B1 (EA)
Title: Collector compositions and methods of using the same
Inventor: NAGARAJ DEVARAYASAMUDRAM R
IPC: B03D101/02
Filed: 2012-10-17
Abstract: Provided are collector compositions for the recovery of value minerals from mineral ore bodies comprising at least one first collector selected from an organic ammonium salt of an organic sulfur-containing acid; and at least one second collector which is a neutral collector, such that the second collector is different from said first collector, along with methods for making and using the same.
Patent EA-031948-B1 (EA)
Inventor: BROWN SU-ELLEN
IPC: C07K16/28
Filed: 2012-11-14
Abstract: Описываются новые антитела к IL-36R или их антигенсвязывающие фрагменты, терапевтические и диагностические способы, соответствующие композиции, а также их применения. Кроме того, в изобретении содержится информация о выделенном полинуклеотиде, кодирующем эти антитела или их фрагменты, клетке-хозяине - продуценте этих антител или их фрагментов, способе получения этих антител или их фрагментов. Раскрыты фармацевтическая композиция, содержащая антитела к IL-36R или их антигенсвязывающие фрагменты, предназначенная для лечения воспалительного заболевания, аутоиммунного заболевания, респираторного заболевания, метаболического заболевания, воспалительного нарушения или фиброза, обусловленного повреждением эпителия, или рака, и фармацевтически приемлемый носитель, а также диагностические наборы для их диагностики.
Patent EA-026584-B1 (EA)
Title: Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
Inventor: PAULUS KERSTIN
IPC: A61K47/18
Filed: 2013-02-28
Abstract: The present invention relates to pharmaceutical compositions, in particular for intravenous administration, which contain {8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetic acid in combination with at least one excipient selected from the cyclodextrins, and water, wherein said compositions have a pH in the range of 7.5 to 8.5, to methods for the production thereof, and to the use thereof to treat and/or prevent viral infections, in particular human cytomegalovirus (HCMV) infections or infections with another member of the Herpes viridae group.
Patent EA-025433-B1 (EA)
Title: Method of roof covering with tile-like roof covering elements
Inventor: CHABOWSKI ANDRZEJ
IPC: E04D3/365
Filed: 2013-07-29
Abstract: Method of a roof covering with tile-like roof covering elements, in which the lower transversal step has got fixing sunken embossing well-fitting to the bend of the upper transversal step of an adjacent roof covering element placed over the former one, performed according to fixed procedure, preferably with use of prefabricated assembling embossments and holes, exploiting embossments at a corner of the roof covering element and an element fixed to a roof with mounting device at one end and its the other end clamps an edge of the roof covering element to the roofing characterised in that the left edge (1.1) of an initial sheet (1) stabilized by fastening with at least one screw to a roof batten (3) is covered by the right edge (4.1) of the second sheet (4). The sheets are mounted by a screw placed through the right lower assembling hole (4.2) of the second sheet (4) and the left lower assembling hole (1.2) of the initial sheet (1). Then the second sheet (4) is stabilized by mounting at least of one screw to a roof batten (3). The lower edge (5.1) of the third sheet (5) is put onto the upper edge (1.3) the initial sheet (1). These sheets are mounted by a screw placed through the right lower assembling hole (5.2) of the third sheet (5) and the right upper assembling hole (1.4) of the initial sheet (1) and at the same time, the left lower assembling hole (5.3) of the third sheet (5) appears over the right upper assembling hole (4.3) of the second sheet (4). Then the right edge (6.1) of the fourth sheet (6) is put onto the left edge (5.4) of the third sheet (5), whilst the lower edge (6.2) of the fourth sheet (6) is placed onto the upper edge (4.4) of the second sheet (4). The fourth (6) and the second (4) sheets are mounted by a screw applied through, preferably, the middle lower assembling hole (6.6) of the fourth sheet (6) and through the middle upper assembling hole (4.8) of the second sheet (4). The junction comprised of corners of four sheets is mounted with a screw applied through the right lower assembling hole (6.4) of the fourth sheet (6), the left lower assembling hole (5.3) of the third sheet (5), the right upper assembling hole (4.3) of the second sheet (4) and through the left upper assembling hole (1.5) of the initial sheet (1). Every time, the bend (5.7) or (6.7) - preferably straight - of the lower edge end (5.1) or (6.2) of a sheet put onto a covered one, is placed in a semicircular deflection (1.6) or (4.9) of the sheet to be covered.
Patent EA-024766-B1 (EA)
Title: Bonding composition for mineral wool based on reducing saccharide and hydrogenated saccharide, and insulating products obtained
Inventor: JAFFRENNOU BORIS
IPC: D04H3/12
Filed: 2012-07-26
Abstract: The present invention relates to insulation products based on mineral wool, in particular glass wool or stone wool, which includes at least one reducing saccharide, at least one hydrogenated saccharide, and at least one polyfunctional crosslinking agent, the hydrogenated saccharide(s) accounting for 10 to 90% of the total weight of reducing saccharide(s) and hydrogenated saccharide(s). The invention also relates to the resulting mineral-fiber insulating products and to the method for manufacturing same.